RxDoctor Payments Data

Patrick Magnus, MD

Interventional Cardiology · Concord, NHNPI 1063438612

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Abbott at 43.4% of the total. Reporting peaked in 2022 at $535 and has fallen 51.9% since, to $258 in 2025. That places this record below the midpoint for interventional cardiology clinicians in NH, where the typical reported total is $5,309.

$2,386in general payments, 2019–2025

Across 71 payments — averaging $33.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Edwards Lifesciences$501
  • Abiomed$339
  • Boston Scientific$140
  • Shockwave Medical, Inc$100
  • Chiesi USA, Inc.$99
  • plus $172 from 5 others

What the payments were for

  • Food & beverage$2,386100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,386 in reported general payments places this provider in the 25th percentile of 26 interventional cardiology providers in New Hampshire.

See all interventional cardiology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$148,648
Medicare patients
753
Services billed
1,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$74,132
XareltoRivaroxaban26$33,553
EntrestoSacubitril/Valsartan28$27,288
Metoprolol Succinate79$1,406
Atorvastatin Calcium76$668
ClopidogrelClopidogrel Bisulfate61$657
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$537
Rosuvastatin Calcium35$320
Furosemide57$247
Amiodarone Hcl13$234
Torsemide15$213
Metoprolol Tartrate37$171
Isosorbide Mononitrate ErIsosorbide Mononitrate23$164
Amlodipine Besylate34$126
Carvedilol18$121

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →